STAT+: GSK sees its return to cancer starting to pay off

MADRID — In the past week, a GSK cancer drug picked up an approval for another tumor type, the company unveiled the first data from a global study of a promising next-generation chemotherapy, and a medicine that the firm has licensed got the…

Read the full story at STAT ↗